Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
Monocyte activation test for parenteral drug contaminants developed
September 5th, 2004
Researchers have developed a monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs. "An optimized test designed for an in vitro monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs is described, together with ways to address the inherent variability of such assays in which cells are cultured using 96-well plates. The test preparation is cultured with peripheral blood mononuclear cells (PBMNC) and the contaminants in the test article stimulate the release from the cells of the endogenous pyrogenic cytokine interleukin-6 (IL-6)," scientists in England report. "The test...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
